Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.

MLA

Paul, S., et al. “Letter: Infliximab de-Escalation Based on Trough Levels in Patients with Inflammatory Bowel Disease.” Alimentary Pharmacology & Therapeutics, vol. 42, no. 7, Oct. 2015, pp. 939–40. EBSCOhost, https://doi.org/10.1111/apt.13335.

APA

Paul, S., Roblin, X., & Peyrin, B. L. (2015). Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 42(7), 939–940. https://doi.org/10.1111/apt.13335

Chicago

Paul, S., X. Roblin, and Biroulet, L. Peyrin. 2015. “Letter: Infliximab de-Escalation Based on Trough Levels in Patients with Inflammatory Bowel Disease.” Alimentary Pharmacology & Therapeutics 42 (7): 939–40. doi:10.1111/apt.13335.